Likewise, UCEC and ACC patients with high ADAR1 expression had poor progression-free survival (PFS), and KIRP and ACC patients with high ADAR1 expression had poor disease-free survival (DFS) (Figures 3(i)–3(l)). This evidence concerns the gene ADAR and adrenal cortex carcinoma.